Treatment with interleukin-2 in malignant pleural mesothelioma: Immunological and angiogenetic assessment and prognostic impact

British Journal of Cancer

Volumn 101, Issue 11, 2009, Pages 1869-1875

  Al, G ^a   Boldrini, L ^a   Lucchi, M ^a   Picchi, A ^a   Dell'Omodarme, M ^b   Prati, M C ^b   Mussi, A ^a   Corsi, V ^a   Fontanini, G ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INFN SEZIONE DI PISA   (Italy)

Author keywords

Interleukin 2; Malignant pleural mesothelioma; Prognosis; Tumour microenvironment

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHYMASE; INTERLEUKIN 2; PARACETAMOL; TRANSCRIPTION FACTOR FOXP3; TRYPTASE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MAST CELL; MICROVASCULATURE; PLEURA MESOTHELIOMA; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MAST CELLS; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TRYPTASES;

EID: 70549105095     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605438     Document Type: Article

References (50)

1. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25+ Foxp3+ regulatory T cells in cancer patients. Blood 107:2409-2414
2. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, Bofill M, Krajewski S, Reed JC, Salmon M (1996) Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal:selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 26:294-299
3. Al̀ G, Boldrini L, Lucchi M, Mussi A, Corsi V, Fontanini G (2009) Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor. J Thorac Oncol 4:348-354
4. Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, Johnston MR, de Perrot M (2008) Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 135:823-829
5. Armstrong AC, Eaton D, Ewing JC (2001) Science, medicine, and the future:cellular immunotherapy for cancer. BMJ 323:1289-1293
6. Astoul P, Picat-Joossen D, Viallat J-R, Boutin C (1998) Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma. A phase II study. Cancer 83:2099-2104 (Pubitemid 28525391)
7. Balkwill F, Mantovani A (2001) Inflammation and cancer:back to Virchow Lancet 357:539-545
8. Cantrell DA, Smith KA (1984) The interleukin-2 T-cell system:a new cell growth model. Science 224:1312-1316
9. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M (2001) Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion:results of a phase II study on 31 consecutive patients. Lung Cancer 31:303-310
10. Chattopadhyay S, Chakraborty NG, Mukherji B (2005) Regulatory T cells and tumor immunity. Cancer Immunol Immunother 54:1153-1161
11. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465 (Pubitemid 32708703)
12. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
13. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
14. DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH (2005) Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 4:342-346
15. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PG, Koten JW (2008) Local therapy of cancer with free IL-2. Cancer Immunol Immunother 57:931-950
16. Fontenot JD, Rudensky AY (2005) A well adapted regulatory contrivance:regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6:331-337
17. Galli SJ, Gordon JR, Wershil BK (1993) Mast cell cytokines in allergy and inflammation. Agents Actions Suppl 43:209-220
18. Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhuis RL, Stoter G (1995) Intrapleural administration of interleukin 2 in pleural mesothelioma:a phase I-II study. Br J Cancer 72:1283-1288
19. Grande C, Firvida JL, Navas V, Casal J (2006) Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17:1-12
20. Herberman RB (1984) Summary:potential of interleukin-2 for the therapy of cancer. J Biol Response Mod 3:527-532
21. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN (2006) Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 27:1086-1095
22. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1030-1031
23. Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T, Katsumata T, Miyazaki M (2005) The relationship of tryptase-and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 28:617-621
24. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404-4408
25. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:a novel mechanism for IL-2. J Immunol 171:5051-5063
26. Ju MJ, Qiu SJ, Gao Q, Fan J, Cai MY, Li YW, Tang ZY (2009) Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci 100:1267-1274
27. Lissoni P, Barni S, Rovelli F, Tancini G (1991) Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology 48:125-127
28. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761
29. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, Strom TB, Zheng XX, Noelle RJ (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002
30. Lucchi M, Chella A, Melfi F, Dini P, Tibaldi C, Fontanini G, Mussi A (2007) Four-modality therapy in malignant pleural mesothelioma:a phase II study. J Thorac Oncol 2:237-242
31. Maggiano N, Colotta F, Castellino F, Ricci R, Valitutti S, Larocca LM, Musiani P. (1990) Interleukin-2 receptor expression in human mast cells and basophils. Int Arch Allergy Appl Immunol 91:8-14
32. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity:effector response to tumour and role of the microenviron-ment. Lancet 371:771-783
33. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H (2008) Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 98:148-153
34. Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM (2001) A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31:67-72
35. Needham DJ, Lee JX, Beilharz MW (2006) Intra-tumoural regulatory T cells:a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 343:684-691
36. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM (2002) Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3:1-17
37. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397-408
38. Rubin JT (1993) Interleukin-2:its biology and clinical application in patients with cancer. Cancer Invest 11:460-472
39. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122-1128
40. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ (2001) A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788-795
41. Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N (1996) T cell-mediated maintenance of natural self-tolerance:its breakdown as a possible cause of various autoimmune diseases. J Autoimmun 9:211-220 (Pubitemid 26163865)
42. Sakkoula E, Pipili-Synetos E, Maragoudakis ME (1997) Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. Br J Pharmacol 122:793-795
43. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells:a common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218
44. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press:Lyon, France
45. Turka LA, Walsh PT (2008) IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. Front Biosci 13:1440-1446
46. Yoshioka T, Miyamoto M, Cho Y, Ishikawa K, Tsuchikawa T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Shichinohe T, Hirano S, Shinohara T, Itoh T, Kondo S (2008) Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma. Br J Cancer 98:1258-1263
47. Yu P, Fu YX (2006) Tumor-infiltrating T lymphocytes:friends or foes Lab Invest 86:231-245
48. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779-791
49. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274
50. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307